WO2007127841A2

WO2007127841A2 - Compositions and methods of preparation thereof

Info

Publication number: WO2007127841A2
Application number: PCT/US2007/067494
Authority: WO
Inventors: Laura A. Yonce; Tessy Kanayinkal; Debra J. Mullins-Hirte; Trevor C. Huang; Rohit Cariappa; Kenneth E. Merte; James R. Keogh; Kevin D. Mcintosh; Brian J. Steffens; Asha S. Nayak; Erick. L. Johnson
Original assignee: Arteriocyte Medical Systems, Inc.
Priority date: 2006-04-26
Filing date: 2007-04-26
Publication date: 2007-11-08
Also published as: WO2007127834A2; WO2007127834A3; US20080044852A1; WO2007127841A3; US9096839B2

Abstract

The present invention provides biological compositions and methods for making the same.

Description

COMPOSITIONS AND METHODS OF PREPARATION THEREOF

BACKGROUND OF TItE INVENTION

Blood coagulation is the result of the complex interaction of a number of protein dotting factors that υceui s through a cascade (FIG 1 ) In general, damage to the vascular endothelium exposes sυbendotheiial structures that attract platelets and induce them to

IO aggregate re\ ersibly The protein thrombin, formed during activation of the coagulation pathwa> , generates insoluble crosslinked fibrils of the protein fibrin and causes the platelets to aggregate irreversibly I he resulting platelet-fibrin clot is an effeeth e barrier against loss of blood from the vascular system and also serv es as a scaffold for subsequent repair of the lining of the blood \ essel

15 Different principles for production of fibrin sealants and the like have been established, and commercial de\ ices employing these methods are a\ ailable and in clinical use I low over, there is still a need in the ait for biological compositions, e.g., tlbrin compositions, and methods for the production thereof

20 BRIEF SUMMARY OF THE INVENTION

The present inx ention is directed to biological compositions and methods for the preparation thereof

In one embodiment of the ind ention, a method for preparing a thrombin composition is provided The method includes contacting whole blood, a component

25 thereof or a fraction thereof, e.g., platelet rich plasma (PRP), platelet poor plasma (PPP), or a combination thereof, with a contact activation agent, e.g., glass wool, an extrinsic coagulation pathw ay initiation agent, e.g., thromboplastin, or combination thereof, to generate a coagulated mass in less than about thirty minutes, obtaining thrombin from the mass and contacting the thrombin with a stabi lizing agent to provide a thrombin

30 composition comprising thrombin having a table-life of more than about six hours The thrombin may be obtained from whole blood, a component thereof or a fraction thereof that has been collected from composition's recipient In one embodiment, the whole blood, component theieof or fraction thoieof, with a source of calcium ions, e.g. , CaCb or a salt thereof The stabilizing agent may include a polyol. PFG. ammonium sulfate, a non- 2 polar solvent, a polar solvent, a methyl isobutyl ketone alcohol, glycol, tricloroacetic acid, acetate salt, and any combination thereof, e.g., ethanoi In one embodiment, the ethanoi is in the range of about 8 % to about 25 % volume/volume, e.g., 10% v/v ethanoi One embodiment of the method includes the proviso that the whole blood, component thereof 5 or fraction thereof, is not contacted with the ethanoi prior to generation of the mass, hi another embodiment, the mass is generated in less than about 10 minutes, e.g., less than about 5 minutes, less than about 3 minutes, or for example, in about 1 minute to about 3 minutes. The table-life of the thrombin in the thrombin composition may be more than 6 hours, e.g., more than 12 hours, or in another embodiment up to 24 hours. For example, in

10 one embodiment the thrombin composition comprises thrombin having biological activity, e.g.. enzymatic activity, for more than six hours In another embodiment, the thrombin composition, when contacted with fibrinogen, is capable of forming a fibrin sealant composition in about i 0 seconds or less In yet another embodiment, the invention provides the thrombin composition prepared by such a method.

15 Further provided is a method of preparing a fibrin composition, the method including fractionating anti coagulated whole blood, a fraction thereof or a component thereof, to obtain a composition comprising fibrinogen, and contacting the fibrinogen composition and a thrombin composition to provide a fibrin composition In one embodiment of the invention, the auti coagulated whole blood, a fraction thereof oi a

20 component thereof, is obtained from the fibrin composition^'s recipient Another embodiment of the invention further includes obtaining a platelet composition comprising platelet rich plasma, platelet poor plasma, or a combination thereof. In yet another embodiment, plasma proteins present in the platelet composition are concentrated, e.g., by cryoprecipitation, chemical precipitation, filtration, dialysis, chromatography,

25 electrophoresis, dehydration, or a combination thereof, e.g., the plasma proteins are concentrated using ethanoi in one embodiment, to provide a plasma protein concentrate, and contacting the concentrate with the fibrinogen composition and the thrombin composition. In one embodiment, the thrombin composition comprises autologous thrombin, recombinant thrombin, bovine thrombin, or a combination thereof Another

30 embodiment of the method further includes contacting the composition with a recornbinantly produced protein, in yet another embodiment, provided is the fibrin composition prepared by such a method. 3

The present invention a! so provides a method of preparing a platelet rich fibrin sealant composition, the method including fractionating antieoaguiated whole Mood, a fraction thereof or a component thereof to obtain a composition comprising platelets., and contacting the platelet composition with a fibrinogen composition, e.g., autologous 5 fibrinogen, recombinant fibrinogen, or a combination thereof, and a thrombin composition, e.g.. recombinant thrombin, autologous thrombin, bovine thrombin, or a combination thereof, to provide a platelet rich fibrin sealant composition. One embodiment of the method further involves concentrating, e.g., via filtration methodology, plasma proteins present in the whole blood to provide a protein concentrate, and

10 contacting the platelet composition, the fibrinogen composition and the thrombin composition with the protein concentrate, e.g., which comprises fibrinogen. Factor XlII, Factor VUI, von Willebrand factor (vWF), or a combination thereof A platelet rich fibrin sealant composition of the invention may also be "fortified" with additional fibrinogen, and may have enhanced mechanical strength as compared to a fibrin sealant composition

15 Also provided is a platelet rich fibrin sealant composition prepared by such a method.

Further provided herein is a method of preparing a fibrin composition, the method including contacting a first portion of antieoaguiated whole blood, a fraction thereof or a component thereof, for example, platelet rich plasma (PRP), platelet poor plasma (PPP), or a combination thereof, with a contact activation agent, e.g. , glass wool, and an extrinsic

20 coagulation pathway initiation agent, e.g.. thromboplastin, to provide a coagulated mass in less than about 30 minutes, extracting thrombin from the coagulated mass to provide a thrombin composition, fractionating a second portion of the antieoaguiated whole blood, a fraction thereof or a component thereof, e.g.. platelet rich plasma (PRP), platelet poor plasma (PPP), or a combination thereof, to obtain a fibrinogen composition and a platelet

25 plasma composition, and contacting the thrombin composition, the fibrinogen composition and the platelet composition to generate a fibrin composition. One embodiment of the invention further comprises contacting the fibrinogen composition, platelet composition, or a combination thereof with a recombinant protein composition Another embodiment further involves contacting the thrombin composition with a stabilizing agent, e.g.. a

30 polyol, PEG, ammonium sulfate, a non-polar solvent, a polar solvent, a methyl isobutyl ketone alcohol, glycol, tricloroacetic acid, acetate salt, or any combination thereof, e.g., ethanol, such as about 8 % to about 25 % volume/volume ethanol, for example, about 10 % volume/volume ethanol. to provide a thrombin composition having a table-life of more 4 than about 6 hours. In one embodiment of the method, the thrombin composition has a table-life of more than 12 hours, e.g., up to 24 hours. Yet another embodiment of the method includes the proviso thai the an ti coagulated whole blood, a fraction thereof or a component thereof is not contacted with ethanol during the generation of the coagulated 5 mass. In an embodiment of the method, the coagulated mass is generated in less than about 10 minutes, for example, less than about 5 minutes, less than about 3 minutes, or in about i minute to about 3 minutes. In one embodiment, the anticoagulated whole blood, a fraction thereof or a component thereof is contacted with a source of calcium ions, e.g., CaCb or a salt thereof. In another embodiment the anticoagulated whole blood, a fraction

10 thereof or a component is obtained from the fibrin composition^" s intended recipient. In one embodiment of the invention, the coagulated mass comprises a fibrin clot Another embodiment further includes contacting the thrombin composition, the fibrinogen composition and the platelet composition with a pharmaceutical agent, therapeutic agent, medical agent, biological agent, or any combination thereof to provide a fibrin

15 composition. Further provided is the fibrin composition prepared by such a method

The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

20

BRIEF DESCRIPTION OF THE DRAWINGS

FIG 1 depicts a coagulation cascade,

FiCj 2 is a flow diagram of one embodiment in accordance with the present invention; FIG 3 is a flow diagram of one embodiment in accordance with the present invention, 25 FlG 4 is a flow diagram of one embodiment in accordance with the present invention;

FIG. 5 is a flow diagram of one embodiment in accordance with the present invention; FIG 6 is a flow diagram of one embodiment in accordance with the present invention; and FlG 7 is a flow diagram of one embodiment in accordance with the present invention.

30 DETAILED DESC RlPTtON OF THE INVENTION

1. Definitions

As used herein, the phrase "fibrin composition^" is a composition including at least fibrin, a component thereof, a derivative thereof, a fraction thereof, 01 a combination 5 thereof When combined, fibrinogen and thrombin may form a layer of fibrin, i.e., fibrin and fibrin monomers align noπ-covalently end to end and side by side to foim branched fibrin strands and a three-dimensional fibrin network Thus, fibrin compositions of the present invention may include fibrin, e.g., autologous fibrin, as well as fibrinogen, e.g., autologous fibrinogen, recombinant fibrinogen, and thrombin, e.g., autologous thrombin,

10 recombinant thrombin, bov ine thrombin, and the Ii ke For example, one type of fibrin composition of the i m ention is a "fibrin sealant" that has at least fibrin and thrombin Fibrin sealants are commercially available, e.g.. CRYOSEAL® (Therm ogenesis, Rancho Cordova, CA), VlVOSTAT¹S⁾ (Vivolution A S, Birkerød, Denmark), and TISSUCOL/TϊSSfcEL® (Baxter AG, Vienna, Austria)

1 S As used herein, the phrase "autologous fibrin composition" refers to a fϊbπn composition having components obtained from or derived from the same individual (i.e., the donor) to whom the composition is to be administered (i.e., the recipient) An autologous fibrin composition of the present invention can include autologous fibrin, autologous fibrinogen, autologous thrombin, or a combination thereof, derived from whole

20 blood, a component thereof or a fraction theieof, that was obtained from a patient io whom the composition is to be applied

Another example of a fibrin composition of the invention is a "platelet πch fibrin sealant" or "PfIFS," which refers to a fibrin sealant that includes platelets, e.g., platelet rich plasma (PRP), fibrin and thrombin

25 "Platelet rich plasma" or "^"PRP" refers to plasma having concentrated platelets, i.e., an increased concentration of platelets as compared to native plasma and plasma PRP ina\ also contain concentrated clotting factors and other proteins, including, but not limited to, fibrinogen. Factor XIH, tactor VlIl and von Willcbrand factor (v\VF)

\ "platelet gel" refers to a composition having platelets, e.g., autologous platelets.

30 and thrombin, e.g., autologous thrombin, recombinant thrombin, bovine thrombin For example, an "autologous platelet gel^" or " APG" refers to a composition hav ing autologous thrombin (AT) and autologous platelets 0

\ "thrombi ii composition" refeis to a composition having thrombin ϊn one embodiment of the invention, a thrombin composition is provided that has an extended "table-life "

An "autologous thrombin composition" refers to a composition having thrombin 5 obtained from the same individual (i.e., donor) to whom the composition is to be administered (i.e., recipient)

B\ "table-iife^" is meant the period of time during which a component of a composition, such as a protein or substance, may be stored at a given temperature and remain suitable for use, i.e , remain "biologically active ^" A "biologically acthe" protein 10 is one lm\ ing enzymatic activity, mitogenic activity, protein binding activity, and/or a teceptor binding act^'iv ity, as measυied ot observed m nvo {i.e.. in the natural ph> siological environment of the protein in the organism) or w vitro (i.e , under laboratory conditions, m tissue culture or ceil free systems, for example) As an example, thrombin is known to have enzymatic activity, e.g , thrombin converts fibrinogen into fibrin by hydrυlyzing 15 peptides {and amides and esters) of L-arginine, as well as mitogeπic activity , e.g. , it induces platelet aggregation Thus, thrombin lm\ ing biological activity is, for example, thrombin that is capable of catalyzing the conversion of fibrinogen into fibiin

As used herein, the phrase "coagulated mass" is meant to refer to the product of the coiivcϊsion of soluble fibunogen to insoluble fibrin, which, undei natn e physiological 20 conditions forms a localized clot < or thrombus) together with platelets that pre\ ents the extravasation of blood components Thus, a "coagulated mass'^" has insoluble crosslinked fibrin strands and or non-crosslink ed fibrin strands, / e , fibrin monomers and/or fibrin pohmers, and may include a fibrin clot Λ "fibrin clot" refers to a cross-linked fibrin clot, or thrombus, which together with platelets under native ph> siological conditions prevents 25 the extrav asati on of blood components

Ph e phrase "plasma protein^" is used interchangeably with the phrases "'serum protein" and "blood plasma psotein," and sefers to a protein found in the blood. </,#., albumin, globulin, blood clotting proteins, etc. A "blood clotting protein" refers to a protein of the coagulation process, such as, but not limited to, fibrinogen, Factor XIII. 30 Factor VHI and von Willebiand factor (vWFl fibrin and thrombin

As used herein "a^" oi "an" means one or more, unless specifics! i> indicated to mean onlv one 7

IL The Blood Coagulation Process

Blood coagulation results in the formation of a fibrin clot i.e., blood clot. Blood coagulation includes clotting cascades, enzymatic processes referred to as the intrinsic pathway and extrinsic pathway (FKJ. 1 ). These pathways each lead to the activation of 5 Factor X, and thereafter join to form a final common pathway resulting in the formation of the cross-linked fibrin clot.

Surfaces, such as negatively charged surfaces, tend to activate the intrinsic pathway, while tissue damage tends to activate the extrinsic pathway. Typically, the intrinsic pathway, also known as the contact activation system, is activated by the

10 adsorption of Factor XII (also known as Hageman factor) onto negatively charged surfaces. The mechanism by which negatively charged surfaces initiate coagulation appears to be aυtoactivation of Factor XII following its adsorption. Factor XII adsorbs onto a surface by displacing previously bound fibrinogen. High molecular weight kininogen (HMWK; HMW-kininogen), which is noiicovalently complexed with Factor Xl

15 and prekallikrein, also displaces bound fibrinogen. The ability of HM-WK to bind to negatively charged surfaces is due, in part, to its positive charge. It appears that HWMK^" s main role is to facilitate the localization of Factor Xl and prekallikrein at the surface where they can be activated by activated Factor XII. Kallikrein (activated prekallikrein) can exert positive feedback on the system through its ability to activate additional Factor XIl,

20 whereas activated Factor Xl in the presence of calcium activates Factor IX (also known as

Christmas factor)

Activated Factor IX, together with calcium, phospholipids, and Factor VIII, causes the activation of Factor X. Factor VlII is thought to be stabilized by von Willebrand factor ( vWF). The final, common pathway starts with activated Factor X, which, in the presence

25 of calcium, phospholipids, and Factor V, converts prothrombin to thrombin. Thrombin, a trypsin-like protease, is responsible for catalyzing the conversion of fibrinogen to fibrin and the subsequent polymerization of fibrin. Two different fibrinopeptid.es, fibrinopeptide A and fibrinopeptide B, are released from fibrinogen during hydrolytic cleavage of fibrinogen by thrombin. These cleaved fibrinogen molecules, also known as fibrin

30 monomers, then polymerize noncovalently to form insoluble fibrin strands. The covalent crosslinking of the insoluble fibrin strands, also known as ligation, occurs in the presence calcium and activated plasma transglutaminase (also known as Factor XUIa or fibrin stabilizing factor). δ

The extrinsic pathway of the coagulation cascade ia activated by tissue factor (also known as factor IH). Tissue factor, which is typically released into the blood following tissue damage, is an enzymatically inert glycoprotein found on the surface of many eel! types Circulating tissue factor interacts with Factor VU, catalyzing the activation of 5 Factor X, thereby joining the common pathway.

As discussed above, fibrinogen is converted into fibrin by thrombin, a proteolytic enzyme. Fibrinogen is made up of three pairs of polypeptides ([A-α][B-β][γ]);. The six chains are covalently linked near their N-terminals through disulfide bonds The A and B portions of the A-α and B-β chains comprise the fϊbrinopeptides, A and B, respectively.

10 The fibrinopeptide regions of fibrinogen contain several glutamate and aspatate residues imparting a high negative charge to this region and aid in the solubility of fibrinogen in plasma Active thrombin, a serine protease, hydrolyses fibrinogen at four arginine-glycme peptide bonds to release an A peptide (fibrinopeptidε A) from each of the two α chains and a B peptide (fibrinopeptide B) from each of the two β chains. A fibrinogen molecule

15 devoid of these fibriπopeptides is referred to as a fibrin monomer, represented by (αβγ);

These fibrin monomers spontaneously aggregate in ordered fibrous arrays referred to as fibrin polymers, which form a weak fibrin clot The clot produced by the spontaneous aggregation of fibrin monomers is stabilized by the formation of covalent cross-links between the side chains of different molecules in the fibrin fiber. In particular, thrombin

20 converts Factor XIlI to Factor XIl Ia, a highly specific transglutaminase that forms peptide bonds between the amide nitrogen of glutamines and e-araino group of lysines in the fibrin monomers, resulting in a cross-linked fibrin clot

III. Anticoagulants of the Present Invention

25 Certain embodiments of the methods of the present invention begin with aπticoagυlated whole blood, which may be prepared by collecting whole blood in a medium containing an anticoagulant, such as sodium citrate (citrate). The act of drawing blood initiates clotting reactions, and, unless something is done to stop the process, a clot generally forms. The formation of a clot is a multi-step process, as described abo\e₅ and

30 several of these steps require the presence of calcium ions. By removing calcium ions from the whole blood, as is the effect when the blood is collected in citrate, the blood may be prevented from clotting. To reinitiate the clot-forming process, calcium may be added back (recalcifi cation). A calcium chelating agent is a chemical that reacts with the 9

calcium present in blood in such a fashion so as to prevent calcium from functioning in Mood coagulation. The most common chelating agent is a salt of citric acid (citrate), since it has the fewest side effects on the components of the coagulation system By collecting blood into a medium containing a calcium chelating agent such as citrate, sample 5 collection and further preparations of the titrated sample may be performed over a time period of up Io several hours

In one embodiment, whole blood may be collected and mixed with a solution of sodium citrate, e.g . 3.8%, in a 9: 1 ratio of blood to citrate collection medium A 3 8% solution of sodium citrate may be prepared by adding 3.8 grams of sodium citrate per 100

10 ml of water. While a 3.8% solution of sodium citrate may be used to collect and preserve blood, the person skilled in this art will recognize that the ratio of sodium citrate to whole blood can vary greatly. For example, the ratio of sodium citrate to whole blood may be in the range of about 10 9 to greater than i 2 9% rnM/^'L, final concentration.

Alternatively, or in addition to, one or more anticoagulants such as heparin,

15 heparin derivatives and/or hepariπ-iike substances, may be used to form or to help form an an ti coagulated whole blood sample. Heparin, a sulphated glycosarninoglycan, is known to inhibit blood coagulation by binding to antithrombin 1IΪ { ATΪI1). a serine protease inhibitor (serpin) found in blood. The binding of heparin to ATUi enhances the activity of the serpin. which, in turn, inactivates the procoagulant serine proteins thrombin, Factor Xa

20 and, to some extent, Factors ΪXa, XIa, and XIIa Heparin accelerates the reactions of

ATOI with the blood-clotting proteases from - 1 ,000 to - 10,000-fold.

Alternatively, or in addition to, one or more anticoagulants such as hirudin, recombinant hirudin, e.g., desirudin, hirulogs, hirudin analogs, e.g., angioraax (bivalirudin) and/or lepirudin, may be used to form or to help form an aniicoagulated

25 whole blood sample. Hirudin is a direct acting thrombin inhibitor.

Alternatively, or in addition to, one or more synthetic thrombin inhibitors, such as argatroban (novastan) and PPACK (dextrophenyjajanine proline arginine chloromethylketone), and Xa inhibitors may be used to form or to help form an anticoagulated whole blood sample.

30

IV. Clotting Activators of the Present invention

One or more coagulation or clotting activators may be used to hasten or accelerate one or more steps of the coagulation process; however, their subsequent removal may be 10

necessary The phrase "clotting ae-ih ator^" is used iπterchangeabi) heieiπ with the phrase ""coagulation activator" and refers to an agent that participates in the coagulation process, e.g., an agent that initiates the intrinsic coagulation pathway, the extrinsic coagulation pathway , or both Examples of clotting activators include, but are not limited to, collagen, 5 celite, contact activation agents and extrinsic coagulation pathway initiation agems By

"'contact activation agent"^' is meant an agent involved in the intrinsic pathway of coagulation, and includes but is not limited to glass, glass beads, diatomaceous earth, ceramics, kaolin, and am combination thereof B) "extrinsic coagulation pathway initiation agent" is meant an agent involved in the extrinsic ρathwa\ of coagulation, and

10 includes but is not limited to tissue factor (TF). thromboplastin, factor Hl, tissue thromboplastin and/ or iecombinant thromboplastin, as well as thrombin In addition, other compounds may be used alone or in combination with other activating compounds or contact activators In addition, compounds such as recombinant thromboplastin, tissue thromboplastin (human or animal), tissue factor fragments, epinephrine, adenosine

15 diphosphate (ADP), thrombin ieceptor activating peptides (TRAPsI arachklonic acid, collagen, and_'Or combinations thereof iriaj be used as a clotting activator in the methods of the present invention

Additionally, physical or mechanical manipulation of the platelet membrane ma\ be used alone oi in combination to speed up the clotting process Mechanical foices may

20 be. for example, liquid, gas or solid in nature

V. Restoration Agents of the Present Intention

A restoration agent, i.e.. an agent capable of reversing or neutralizing the effects of an anticoagulant, may be used in the present invention to restore one or more steps of the

25 coagulation or clot -forming process In one embodiment, the restoration agent comprises a source of calcium ions. e.χ , a calcium salt such as calcium chloride or calcium gluconate Λn\ caicium sait that revesses or neutralizes the anticoagulant ma> be used as a source for calcium ions in the methods described herein For example, organic or inorganic salts may be used as long as they can transfer Ca to serum proteins Suitable

30 organic calcium salts include calcium propionate and calcium acetate Suitable inorganic salts include calcium hydroxide, calcium ammoniate, calcium carbide, caicium carbonate, calcium sulfate, calcium nitrate, and calcium pyrophosphate Substances that are know n or found to be functionally equivalent to calcium chloride in restoring the coagulation 11 activity of citrated blood may also be used For example, any calcium salt that functions in a similar manner to calcium chloride may be used. Similarly, although many Mood coagulation reactions require calcium ions, as cefaclors, airy substance that is known or subsequently found to be functionally equivalent to calcium in facilitating these 5 coagulation reactions may be used, either individually or in combination with calcium, in the practice of the present invention

Alternatively, if the anticoagulant used was heparin, then heparinase or protamine, for example, may be used as a restoration agent to reverse or neutralize the effects of the anticoagulant. The concentrations of one or more restoration agents used to reverse the

10 effects caused by one or more anticoagulation agents will depend in part, upon the concentrations of the one or more anticoagulation agents present in the plasma, e.g , FFF and/or PRP, and the stoichiometry of the chelating and coagulation reactions. In one embodiment of the present invention, the concentrations of the one or more restoration agents used to reverse the one or more anticoagulation agents must be sufficient to achieve

15 clot formation.

In one embodiment of the present invention, one or more restoration agents and/or one or more coagulation activators may be used alone or in combination to restore and/or accelerate one or more steps of the coagulation process, hi certain embodiments, restoration agent may also be a coagulation activator

20

VI. Protecting Groups of the Present Invention

In one embodiment of the present invention, one or more protecting groups may be used to protect one or more functional groups of one or more substances being isolated and/or concentrated. (⁵Or example, carbonyl protecting groups include the formation of

25 cyclic acetaSs. For example, a carbonyl functional compound or substance of interest may be protected by reaction with 1, 2-ethanediol or propane- !, 3-dio! in the presence of an acid catalyst Hie cyclic acetal may be removed when desired in the presence of aqueous acid. Alcohol protecting groups include the formation of acetais, ethers and trial kyi sϊlyl ethers, for example. A hydroxy! functional compound or substance of interest may be

30 protected by reaction with silyl chloride in the presence of a mild base, such as imidazole.

Amine protecting groups include the formation of amides or carbamates, for example Amine protecting groups include the formation of N-acyl derivatives and N-sulfoπyl 12

derivatives, for example A primary amine functional couropound or substance may be protected by the reaction v,ith phthatic anhydride,

VlI. Recombinant Proteins of the Present Invention

5 One or more recombinant proteins and/or substances may be used in the methods of the present invention. For example, recombinant human fibrinogen (rhFg), recombinant thrombin (rhThr) or other clotting proteins and/or factors may be employed. Recombinant proteins possess the same molecular structure as their naturally occurring counterparts, but are produced in non-human systems such as bacteria, yeast, cultured

10 animal cells or even whole animals These surrogate systems may be induced to produce the protein of interest in high quantities under controlled conditions This may be accomplished by transferring an isolated human gene into the host organism

Recombinant proteins may be readily available for use in biological compositions, e.g., a fibrin composition or a thrombin composition, since they are generally stored as dry

15 powders (iyophiiized) at room temperature or colder In one embodiment of the present invention, one or more Iyophiiized proteins and/or substances may be resuspended in an appropriate solvent {e.g , PRP and/or PPP) In addition, the ability to store powdered forms of the recombinant proteins and/or substances increases their stability'

For example, recombinant fibrinogen aud/oi other clotting proteins, such as factor

20 VlH or factor XIIl may be added to either PRP and/or PPP in order to increase the fibrin network created upon formation of a gel or coagulated mass, in one embodiment, recombinant thrombin may be solubslized or dissolved in a calcium chloride solution, for example, if sodium citrate was used as the anticoagulant, in order to form the fibrin composition at the site of action.

25 PRP and PPP, e.g., autologous PIiP and PPP, may be prepared from whole blood, as described herein. Recombinant thrombin may be mixed with the PRP and/or PPP and optionally with recombinant fibrinogen to create a "customizable" fibrin composition For example, autologous PRP may be combined with recombinant fibrinogen and recombinant thrombin to form a platelet rich fibrin composition useful for hemostatic sealing and

30 wound healing. Autologous PRP may be combined with recombinant thrombin to create an autologous platelet gel (APG) composition useful for hemostasis and wound healing In addition, autologous PPP may be combined with recombinant fibrinogen and recombinant thrombin to create a fibrin composition useful for hemostasis and sealing. 13

VIII. Stabilizing Agents of the Present Invention

One or more stabilizing agents, i.e , an agent capable of prolonging the "life" of a protein and/or substance present in one of the compositions of the invention, may be used 5 to prolong the "table-life" of one or more proteins and/or substances in one or more components of a biological composition. By "table-life^{^} is meant the period of time during which the proteins and/or substance may be stored at a given temperature and remain suitable for use, e.g., remain "biologically active.^" As used herein, a "biologically active" protein or substance exhibits an activity such as. for example, an enzymatic

10 activity, a mitogenic activity, a protein binding activity, and/or a receptor binding activity, as measured or observed hi vivo (i.e., in the natural physiological environment of the protein or substance in the organism) or in vitro (i.e., under laboratory conditions, in tissue culture or cell free systems, for example) As an example, thrombin is known to have a variety of biological activities, such enzymatic activity, e.g., thrombin converts fibrinogen

15 into fibrin, e.g. , by hydroiyzing peptides (and amides and esters) of L-argiπine; as well as mitogenic activity, e.g., it induces platelet aggregation. Thus, thrombin having biological activity is. for example, thrombin that may catalyze the conversion of fibrinogen into fibrin.

Exemplary stabilizing agents include, but are not limited to polyois, e.g., glycerol,

20 FECJ; ammonium sulfate; non-polar solvents such as chloroform and the like , polar solvents such as ethanol, methanol, isopropanol, //-propano!, cyclohexanol, acetone, DMSO, and the like; methyl isobutyl ketone alcohols; glycols; tricloroacetic acid; acetate salt; and/or combinations thereof may be used. In one embodiment temperature, e g , temperatures colder than physiological temperature may he used as an "agent^" to stabilize

25 one or more proteins and/or substances.

Any agent that binds or otherwise renders proteins and/or substances that contribute to the degradation of thrombin "unavailable" may be used as a stabilizing agent. Any agent that preserves thrombin and/or prevents the denaturation of thrombin, i.e., maintains or improves the activity of thrombin may be used as a stabilizing agent.

30 Stabilizing agents include, for example, agents that prevent the autolytic degradation and/or denaturation of thrombin, agents that remove and/or inhibit the negative regulators of coagulation such as antithrombin 111, tissue factor pathway inhibitor (TFPI), and/or components of the protein C system (protein C, protein S and thrombomodulin). 14

In one embodiment of the methods described herein of the present invention, ethano! may he used as a thrombin stabilizing agent. The addition of ethanol to a thrombin preparation can precipitate antithrombin Hl (ATlH) {via ethano! fractionation), thus reducing ATIITs inhibitory function in the intrinsic coagulation pathway for the 5 catalysis of prothrombin to thrombin In certain embodiments, ethanol in the range of about 8% to about 25% (vol/vol) may be used as a stabilizing agent to provide a thrombin composition having a table-life of more than about six hours

While not intending to be bound to any particular theory regarding the mechanism of action, it is believed that the carboxylic group of the thrombin reacts with the hydroxyl

10 group of the alcohol forming an ester, thus preventing the autolytic degradation of thrombin In addition or alternatively, it is believed that the presence of an organic solvent affects protein folding, which in turn affects the activity of thrombin, an effect that may not be permanent. Again, not wishing to be bound by theory, when a thrombin composition comprising an organic solvent is combined with a blood plasma component,

15 such as platelet rich plasma, platelet poor plasma, etc , the concentration of the organic solvent decreases, this in turn can increase the activity of thrombin. Thus, the organic solvent may act as a "switch," controlling the activity of thrombin In addition, or as an alternative, the stabilizing agents, for example, as described herein, may denature and thus 'remove" proteins that inactivate thrombin, e.g., antithrombin 111 Protein C (and protein

20 S) typically regulates the formation of thrombin under normal, physiologic conditions

While not being bound by theory, the stabilizing agents may denature and effectively 'remove' Protein C (and Protein S), thus allowing any remaining prothrombin to be converted into thrombin Therefore, thrombin concentrations may increase after the addition of one or more stabilizing agents as discussed herein

25 In one embodiment of the present invention, cold temperatures may be used to inhibit and/or prevent the degradation of one or more proteins and/or substances of the biological compositions described herein In certain embodiments, cold temperatures can minimize degradation of one or more proteins and'or substances of the composition without negatively affecting performance, e.g., biological activity, when the composition

30 is wanned just prior to forming the fibrin composition, e.g., a platelet rich fibrin composition. In one embodiment, temperatures colder than physiological temperature can inhibit and/or prevent autocatalytk activity of thrombin, and are used to stabilize thrombin preparations prepared according to one or more the methods of the present invention. 15

IX. Additional Agents Useful in the Compositions and Methods of the Present Invention

5 In one embodiment of the present invention, recombinant human agents or substances, e g., proteins and/or enzymes, may be used to form a biological composition, e.g.. recombinant human thrombin and/or recombinant human fibrinogen may be used. In an alternative embodiment of the present invention, agents or substances, e.g . proteins and/or enzymes, from a non-human source may be used to form a biological composition,

10 e.g._H bovine or porcine thrombin and/or bovine or porcine fibrinogen may be used, In yet another embodiment, a complete recombinant mixture of proteins in buffer and recombinant thrombin may be used to generate a biological composition. For example, recombinant thrombin, one or more recombinant proteins, e.g , recombinant fibrinogen, PPP may be mixed together to form a fibrin composition according to one embodiment of

15 the present invention. If the composition comprises fibrinogen, then the fibrin composition may be used, for example, as a fibrin sealant composition.

In one embodiment of the present invention, one or more anticoagulants, clotting activators, restoration agents and/or stabilizing agents, as described herein, may be used in the method of making a biological composition, e g , a fibrin composition.

20 In one embodiment of the present invention, a biological composition, e.g . a fibrin composition, of the present invention may be used as a delivery vehicle for one or more agents or substances including pharmaceutical agents, therapeutic agents, medical agents and/or biological agents Agents that may be added to a fibrin composition of the present invention may be found in nature (naturally occurring) or may be chemically synthesized

25 by a variety of methods well known in the art. One or more components of a fibrin composition including agents that may be added to the fibrin composition may be derived from humans and/or animals and/or they may be derived from various recombinant techniques.

A fibrin composition of the present invention may include one or more agents or

30 substances described herein, or any substance suitable for providing a desired effect, e.g.. a biological effect, a chemical effect a mechanical effect, an electrical effect and/or a physiological effect. In one embodiment of the present invention, it is envisioned that selected fragments, portions, derivatives, or analogues of one or more of the 16 pharmaceutical agents, therapeutic agents, medical agents and/oi biological agents ma) be added to a fibrin composition of the present invention Examples of pharmaceutical agents, theiapeuiic agents, medical agents and_'O* biological agents that may be added to a fibrin composition of the present invention include, but are not limited to, drugs. 5 anticoagulant agems, antithrombotic agents, including heparin, heparin deiivati\cs, hirudin, and PPAC¹K (dextrophenyl alanine proline arginine ehloroinethylketone), thromboh tic agents including urokinase and/ or tissue t>pe plasminogen activator, clotting agents, platelet agents, antibodies, antigens, defense agents, growth factors, neurotransmitters, c\tøLiπes, blood agents, tissue agents, regulator agents, transport

10 agents, fibrous agents, proteoglycans, hyaluronic acid, fatty acids, analgesic agents, anesthetic agents, including lidocaine, bupi\acaine. and iopivacaine. antiniiciobiai agents. including triclosan, cephalosporins, aminogly cosides, and nitorfurantoin. antibacterial agents, including bacteriocidal and bacteriostatic agents, bacterial agents, antibiotic agents, including adriαmycin, erythromy cin, gcntamycin. vancomycin , penicillin, tobramycin,

15 antifungal agents, antiparasitic agents, amhira! agents, viral agents, en/ymes, en/yinc inhibitors, glycoproteins, growth factors, lymphokincs. cy tokines, hormones, steroids, giucocorticosteroids, immunomodulators, immunoglobulins, minerals, neuroleptics, carbohydrates, polysaccharides, amino acids, proteins, peptides, polypeptides, lipopioieins, tumoricidal compounds, tumoi static agents, toxins, vitamins, including

20 Vitamin A, Vitamin P., Vitamin B. Vitamin C. Vitamin D. or derivathes thereof, oligonucleotides, libozymes, genetic agents, anti-sense gene agents, DNA segments, RNA segments, DMA compacting agents, gene Vector systems, nucleic acids, including recombinant nucleic acids, naked UNA. cDNA, RNA, genomic DNA, cϋNA. RIsA in a non-infectious vector or in a \iral \ector which may have attached peptide targeting

25 sequences, antisense nucleic acid (RNA or DNA), and DNA chimeras which include gene sequences and encoding for ferr> proteins such as roembiane translocating sequences ("M I S") and herpes simplex \ bus- 1 ("VP22"), liposomes, ionic agents, cationic agents, anionic agents, monomers, polymers, catalysts, lectins, ligands, d> es, including dyes which act as biological ligands. antioxidants, including probucol and retinoic acid,

30 angiogenic agents, anti-angiogemc agents, agents that block smooth muscle cell proliferation, including rapamycin, angiopeptin, and monoclonal antibodies capable of blocking smooth muscle cell proliferation, anti-inflammatory agents, including dexamethasone, prednisolone eoπicosterone, budesonide, estrogen, sulfasalazine, acetyl 17 salicylic acid, and mesalamine. calcium entry blockers, including verapamil, diitiazern and nifedipine, antineoplastic agents, antiproliferative agents, anti-mitotic agents, including paclitaxel, 5-Ωuorouracii, methotrexate, doxorubicin, daimorubicin, cyclosporine, eisplatin, vinblastine, vincristine, epoihilones, endostaiin, angiostatin and thymidine kinase 5 inhibitors, nitric oxide (NOj donor agents, including lisidomine, molsidomine, L-arginiπe,

NO~protein adducts, NO-carbohydrate adducts, polymeric or oiigomeric NO adducts, an RGD pepti de-containing agent, an ti -thrombin agents, platelet receptor antagonists, anti- tJirombin antibodies, anti-platelet receptor antibodies, enoxaparin, Warafln sodium, Dicumarol, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet factors,

10 vascular cell growth promoters, including growth factors, growth factor receptor antagonists, transcriptional activators, and translations! promoters, vascular cell growth inhibitors, including growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitor)' antibodies, antibodies directed against growth factors, bifunctiona! molecules consisting of

15 a growth factor and a cytotoxic, bi functional molecules consisting of an antibody and a cytotoxin, cholesterol -lowering agents, vasodilating agents; agents which interfere with endogenous vasoactive mechanisms, survival genes which protect against cell death, including anti-apoptotic BcI -2 family factors and Akt kinase, and combinations thereof. Examples of polynucleotide sequences that may be used in one embodiment of the

20 present invention include DNA or RNA sequences having a therapeutic effect after being taken up by a cell. Examples of therapeutic polynucleotide agents include anti-sense DNA and RNA; DNA coding for an anti-sense RNA; or DNA coding for tRNA or rRNA to replace defective or deficient endogenous molecules. The polynucleotide agents of one embodiment of the present invention may also code for therapeutic proteins or

25 polypeptides. A polypeptide may be a translation product of a polynucleotide regardless of size, and whether glycosylated or not. Therapeutic proteins and polypeptides according to one embodiment of the present invention may include those proteins or polypeptides that can compensate for defective or deficient species in an animal, or those that act through toxic effects to limit or remove harmful cells from the body, for example in addition, the

30 polypeptides or proteins useful in one embodiment of the present invention may include, without limitation, angiogenic factors and other molecules competent to induce angiogenesis, including acidic and basic fibroblast growth factors, vascular endothelial growth factor, hif- lα, FGF-L FGF-2. IGF. epidermal growth factor, transforming growth 18 factor alpha and beta, platelet-derived endothelial growth factor, pialeiel-derived growth factor, tumor necrosis factor alpha, hepaiocyte growth factor and insulin like growth factor, growth factors, eel! cycle inhibitors including CDK inhibitors, anti-restenosis agents, including pi 5, pi 6, pi 8, pi 9, p2i, p27, p53, p57, Rb, πfkB and E2F decoys, 5 thymidine kinase ("TK") and combinations thereof and other agents useful for interfering with cell proliferation, including agents for treating malignancies and combinations thereof. Still other useful agents or factors that may be used in one embodiment of the present invention, which may be provided as polypeptides or as DNA encoding these polypeptides, include monocyte chemoattraetant protein ("MCP- 1 "), and the family of

10 bone raorphogenic proteins ("BMPV), including BMP-2, BMP-3, BMP-4, BMP-5, BMP- t> (Vgr-1 ), BMP-7 (OP-I ), BMP-8, BMP-9, BMP-10, BMP-U, BMP-! 2, BMP-13, BMP- 14, BMP-1 5, and BMP-16. For example, BMFs such as BMP-2, BMP-3, BMP-4, BMP- 5, BMP-6 and/or BMP-7 may be used. These dirøeric proteins can be provided as homodimers, hetcrodimers, or combinations thereof, alone or together with other

15 molecules. Alternatively or. in addition, agents capable of inducing an upstream or downstream effect of a BMP may be used. Such agents may include any of the "hedgehog" proteins, or the DNA's encoding them.

In one embodiment of the present invention, micro-particles, e.g , biodegradable micro-particles, may be added to a fibrin composition of the present invention For

20 example, micro-particles small enough for injection through a needle but too large to lit into capillaries and venules, may be added to a fibrin composition In one embodiment, the micro-particles may be impregnated with one or more pharmaceutical agents, therapeutic agents, medical agents and/or biological agents that can elute, e.g., as the micro-particles degrade

25 In one embodiment of the present invention, a fibrin composition may include one or more chemicals, e.g , polymers and/or chemical cross-linkers, that may chemically bind to one or more chemical constituents, e.g., proteins, located within tissue For example, one or more proteins that can chemically bind to the surface of one or more cell types contained in tissue may be used according to one embodiment, hi one embodiment,

30 polymers that can covalently bind to primary amine groups (-NHi) of proteins contained within target tissue may be used. Several embodiments of a fibrin composition may include pro-inflammatory molecules, such as histamine, cytokines, and/or chemokines At least one embodiment of a fibrin composition of the present invention may include one or 10 more contrast agents that may be for visual identification of the fibrin composition Examples of contrast agents include, but are not limited, to X-ray contrast (e.g., IsoVυe), MRI contrast (e.g., gadolinium), and ultrasound contrast (e.g., echogenic or echo-opaque compounds).

5 In one embodiment of the present invention, one or more cells or cell types may be added to a fibrin composition of the present invention. For example, cells such as bone marrow cells, stem cells, mesenchymal stem ceils, pi uri potent cells, myocytes, cardiocyte precursor cells, undifferentiated contractile cells and/or cells capable of maturing into actively contracting cardiac muscle cells may be added to a fibrin composition of the

10 present invention. Typically, undifferentiated contractile cells differentiate to form muscle cells, however, they can be fibroblasts that have been converted to myoblasts ex vivo, or any of a wide variety of immunologically neutral cells that have been programmed to function as undifferentiated contractile cells Cells of mesodermal origin that form contractile cells may be added to a fibrin composition of the present invention, and include

15 skeletal muscle cells, heart muscle cells, and smooth muscle cells, as well as precursor cells to the cells, such as pi uri potent stem cells, embryonic stem cells, mesodermal stem cells, myoblasts, fibroblasts, and cardiomyocyres. Suitable cells for use in the present invention may include umbilical cells and skeletal muscle satellite cells Suitable cells for use in the present invention may also include differentiated cardiac or skeletal cells, such

20 as cardiomyocytes, rayotubes and muscle fiber cells, and the like, fells that may be used according to one or more embodiments of the present invention may be autologous, allogeneic or xenogenie, genetically engineered or non-engineered Mixtures of various cell types may be used. Cells capable of establishing healthy tissue in damaged or diseased tissue areas or cells aiding in the angiogenesis process may be used according to

25 one or more embodiments of the present invention.

One embodiment of the present invention enables one or more agents, substances and/or components, as described earlier, to be added or mixed prior to delivery by one or more delivery devices. For example, in one embodiment of the present invention, one or more agents or substances as described herein may be added to the thrombin. PPP and/or

30 PRP and protein mixture prior to deliver)_' of a tlbrin composition to a patient

Alternatively, in one embodiment of the present invention, one or more agents or substances as described herein, for example, may be added to the thrombin component prior to mixing the thrombin, PPP and/or PRP and protein components together 20

Alternatively, in one embodiment of the present invention, one or more agents or substances as described herein, for example, may be added to the PPP and/or PRP components prior to mixing the thrombin, PPP and/or PRP and protein components together. Alternatively, in one embodiment of the present invention, one or more agents 5 or substances as described above, for example, may be added to the protein component prior to mixing the thrombin, PPP and/or PRP and protein components together.

X. Thrombin Compositions of the Present invention

In one embodiment, the present invention provides a method for preparing a

10 thrombin composition, for example, an autologous thrombin (AT) composition. For example, an AT composition can be prepared by extracting thrombin from whole blood, <\£., aπtkoagulated whole blood, a component thereof such as blood plasma and/or a fraction thereof such as platelet poor plasma, platelet rich plasma, and the like, that is obtained from a subject to whom the thrombin composition is to be administered, i.e., the

15 red pi en I of the composition .

As discussed above, thrombin is a serine protease that proteolytkally cleaves fibrinogen Io form fibrin, which is ultimately integrated into a cross) inked network. In certain embodiments of the present invention, the process begins upon restoration of the whole blood, component thereof or fraction thereof, such as PRP and/or PPP. In one

20 embodiment, this results in a "coagulated mass," which as referred to herein includes both insoluble crosslinked fibrin strands and/or non-cross! inked fibrin strands. According to the methods provided herein, the time it takes to form the coagulated mass, i.e., the "coagulation time,^"' also referred to as clotting time and/or blood clotting time, may be reduced as compared to conventional thrombin preparation techniques. Once formed, the

25 coagulated mass is triturated by high speed centrifugation or squeezed through a mesh to provide serum containing thrombin. The thrombin may then be used, for example, to prepare a fibrin composition according to at least one method disclosed herein

In another embodiment, thrombin is obtained from a coagulated mass prepared by contacting a source of thrombin and a source of fibrinogen with a contact activation

30 agent(s), extrinsic coagulation pathway initiation agent(s) or combination thereof. As discussed infra, the blood coagulation process, also known as the coagulation cascade, can be activated through either the extrinsic or intrinsic pathway. These enzymatic pathways share one final common pathway, resulting in formation of a crosslinked fibrin clot The 21 first step of the common pathway of the coagulation cascade involves the proteolytic cleavage of prothrombin by the Factor Xa/Factor Va prothrotnhinase complex to yield active thrombin.

It has been discovered by the present inventors that the presence of ethanol during 5 the production of thrombin from whole blood, a component thereof or a fraction thereof, such as PRP and/or PPP, increases (slows down) the plasma clotting time Thus, in one embodiment of the present invention, ethanol is not present during the production of thrombin. When ethanol is not present, for example, as a chemical precipitation agent, during the processing of blood into fibrinogen and/or thrombin, the time it takes to form a

10 coagulated mass can be reduced from about 30 minutes at room temperature to in the range of about 2 minutes to about 4 minutes at room temperature, in addition, in certain embodiments of the methods, thromboplastin is used to accelerate plasma clotting time, A stabilizing agent, for example, ethanol and/or a reduced temperature, may be used to prolong the "table-life" of a thrombin composition made according to the methods

15 described herein The addition of a stabilizing ageπt{s) to a thrombin composition may provide a thrombin composition having a biological activity of more than 6 hours, for example, about 12 hours or up to about 24 hours The thrombin in such a composition has a biological activity, e.g., enzymatic acth ity, for more than 6 hours when stored at room temperature. For example, a thrombin composition prepared according to the present

20 invention may be used in combination with a source of fibrinogen to form a fibrin composition that "gels'^" or forms a cross-linked fibrin clot in about 5 seconds or less alter having been stored for about 6 hours or more at room temperature. In another embodiment, a thrombin composition prepared according to the present invention may be used in combination with a source of fibrinogen to form a fibrin sealant composition in

25 about ten seconds or less.

Assays for determining thrombin activity are known to the art and include, e.g.. amidolytic assays, clotting assays, etc, In addition, in vitro analysis of the biological activity of thrombin may be conducted using a chromogenic substrate measured spectrophotometrically Using stabilizing agents according to the methods of the present

30 invention may extend the table-life of a thrombin preparation. Thus, by the addition of a stabilizing agent to the thrombin preparation, the table-life of thrombin may be extended, for example, by 3 or more hours. In certain embodiments of the methods disclosed herein, a stabilizing agent(s) is added to a thrombin preparation once thrombin is extracted or 22 isolated from whole blond, blood plasma or a fraction or component thereof such aa platelet rich plasma, platelet poor plasma, to provide a thrombin composition PRP and 'or PPP, Oi a combination oi fraction theϊcof

5 XI. Cen trif ligation

Λs shown in FIGs 2-7, whole blood, e.g., ami coagulated whole blood, a component thereof, e.g., thrombin, or a fraction thereof, e.g., plasma, PPP or PRP, is fractionated, eg , centrifuged, in certain embodiments of the present ins ention For example, anticoagulated whole blood is centrifuged using the Medtronic Magellan®

10 autologous platelet separator to form platelet rich plasma (PRP) and_'Or platelet poor plasma (PPP) (FiGs 2-7) In one embodiment of the present invention, anticoagulated whole blood is centrifuged at a rate of approximately 200-800 r c Fs for about 4 to about 40 minutes to provide two liquid phases

In certain embodiments, centrifugation occurs at refrigerated temperatures For

15 example, amicoaguiaied whole blood is centrifuged at refrigerated temperatures and o00 r c f 's for about 4 minutes to provide two liquid phases, e.g., a top PRP phase, and a bottom phase thai is amicoagulated whole blood minus the platelet rich plasma The PR.P is then genth drawn off and saved in a first container The PRP phase nia\ be further centrifuged, eg , at a iate of appioximately 1000-2000 i c f S foi about 3 to about 12

20 minutes In one embodiment, the PRP phase is centrifuged at refrigerated temperatures and 1200 r c Fs for about 3 to about t» minutes This higher rate of ccntrifugaiion results in the red blood cells, white blood cells and platelets being spun out of the PRP phase, thereby further concentrating the cellular components The resulting PPP, following remov al of the concentrated cellular components, is then sa\ed in a second container

25 The first container, second container or both, may ha\e either a wettable surface

(such as silica, diatcmaceous earth, kaolin, etc ) or a πoπ-wettahie suiiace (such as plastic, siliconized glass, etc ) Because surfaces pla> a role in activating blood coagulation, the choice of surface for either the first or second container is dependent on whether or not clot formation and/or the activation of one or more steps of the coagulation process is

30 desired In one embodiment, a plastic syringe may be used to collect the PRP and or the

PPP

In one embodiment of the present invention, the PRP may include plasma with an above-normal amount of platelets ϊn another embodiment, the PRP may include plasma,, 23 platelets, white blood cells, 01 a combination thereof In yet another embodiment, the PRP may include additional components, e.g . red blood cells In \ et another embodiment, the PRP includes a higher concern* a ti on of platelets ilian the starting sample, e.g., the anh coagulated whole blood sample

5 In one embodiment of the picsent invention, the PPP may include plasma with a below -normal amount of platelets, c ^f., plasma that is, free of platelets and. oi plasma fiee of white blood cells In another embodiment, fresh frozen plasma may be substituted for PFP In yet another embodiment, the FPF may include additional components, e.g., red blood cells In yet another embodiment the PPP includes a lower concentration of

10 platelets than the starting sample, e.g._H the an ti coagulated whole blood sample

In anothes embodiment, PPP piepated from whole blood as described above, then cooled and further centrifugcd at refrigeration so as to provide a protein concentrate, e.g., plasma having concentrated fibrinogen and other blood coagulation proteins In one such embodiment, for example, as shown in MG 7, PPP is contacted with iθ% ethanol prior to

15 iefrigerated ccntrifugaiion

XlL Methods of Concentrating Plasma Proteins

The fibrin compositions and 'Or thrombin compositions of the present invention can be piepajcd by fractionating whole blood, ϊemoving cellular components, and Ui en

20 applying various methods to isolate fibrin and or thrombin from the resulting blood plasma fractions Alternatively, the fibrin compositions and/or thrombin compositions ma\ be prepared directly from whole blood Methods such as er\ oprecipitation, ph\ sico- chemical precipitation, the use of micro-filter technology, density gradient technology, dial) sis, chromatography, electrophoresis and dehydration and the like may be used, for

25 example, to isolate and or concentrate one or more components used in the preparation of a biological composition, e.g , a fibrin composition In one embodiment of the present invention, one ot more clotting pioteins, e.g „ flbύnogen, t-actos VHl and Factor XIIL may be isolated and or concentrated, for example, from a blood plasma fraction In one embodiment of the present invention, fibrinogen concentration in a biological composition

30 of the present invention is greater than about 3 tunes the normal fibrinogen conccntiation in whole blood and/or plasma 24

A. Oyoprecipitation

As discussed above, in one embodiment of the present invention a fraction of whole bloυd, i.e., PPP, is centrifuged at refrigerated temperature with ethanol to concentrate PPP. Thus, cryoprecipitation can be used in the methods of the invention to 5 concentrate proteins, such as clotting proteins that are present in whole blood, a fraction thereof or a component thereof. Cryoprecipitation methods are known in the art, see for example U.S. Patent Nos 4,928,603 and 4,627.879.

In one embodiment, FPP and/or PRP may be frozen, e.g., at a temperature below O⁰C such as -80⁰C, for about 1.5 to 12 hours. Then, the frozen PPP and/or PRP is slowly

10 thawed to provide an insoluble protein precipitate that can then be collected by certtrifugatϊon, e.g., at approximately 1000 r c.f "s for approximately 15 minutes. For example, frozen PPP is control lably thawed at about 1 to about 4⁰C for approximately about 2 to about SQ hours. The sample is then centrifuged for approximately 10 to 15 minutes at approximately about 1 to 4⁰C to separate precipitated proteins. The supernatant

15 is then removed. The precipitated and centrifuged pellet of concentrated proteins is then resuspended at a temperature greater than 6"C using either a portion of the supernatant or other solvent The amount of solvent used to resuspend the protein will determine its final concentration. For example, in one embodiment of the present invention, the precipitated and centrifuged pellet of concentrated proteins is resuspended in plasma at a temperature

20 of approximately about 22 to 3TC ϊn one embodiment, fibrinogen, e.g.. autologous fibrinogen, is obtained from a sample of whole blood via cryoprecipitation and added to a platelet gei, e.g., an autologous platelet gel, which results in a platelet gel having enhanced mechanical properties, e.g., enhanced mechanical strength, as well as enhanced clotting time

25

B, Chemical Precipitation

Using chemical precipitation methods, certain blood proteins or substances may be precipitated while others are partially precipitated or remain in solution using organic reagents such as ethanol, isopropanol. and/or polyethylene glycol (PEG). Additional 30 precipitation agents include inorganic salts or salt solutions, including but not limited to ammonium sulfate, methanol, glycol, glycine, acetone, cyelohexaπol, chloroform, tricloroacetic acid, acetate salt and/or combinations thereof. See, for example, U S Patent application publication Nos 20040120942 and 20040208786; U S Patent Nos. 5,643, 192, 25

5,795,780 and 6,472,162; and Kaetsu et al , ThrtMbosis R^eareh. 90: 1001-109 (1098), Additional exemplar)- precipitation agents include, but are not limited to, non-detergent surphobeiaines (NDSBs.) and mild denaturing agents.

An alternative method for concentrating one or more proteins and/or substances 5 from whole blood or blood plasma components such as PPP and/or PRP involves the use of one or more chemical additives to precipitate one or more proteins and/or substances. For example, between about 4% and 20% (vol/voi) ethanol may be used in a chemical precipitation method to isolate at least fibrinogen, albumin, cholesterol and various globulins whole blood, PPP and/or PRP, see, for example, Colin el al , J, Am. Cheni.

10 Soc.;68 -450-475 (1946); van Oss, Journal of Protein Chemistry, 8:661-668 (1989).

Ethanol may added to whole blood or blood plasma components such as PRP or PPP to increase the time it takes a clot to form, e.g., the plasma clotting time Thus, in one embodiment of the present invention, ethanol may be used to increase the clotting time to about 30 minutes In addition, ethanol may be used to impact the strength of a biological

15 composition, e.g., a fibrin composition. For example, about 4% to about 20% ethanol may be used to precipitate plasma proteins. Subsequently, the precipitated proteins may be re- dissolved and/or reconstituted in a volume of fresh PRP. PPP, and/or whole blood, for example It was discovered that the concentration of ethanol used to precipitate such proteins affects the strength of a fibrin composition of the present invention For example,

20 a fibrin composition prepared using plasma proteins precipitated using about 4% to about

20 % ethanol was found to have maximum strength, i.e., maximum mechanical strength, In one method of the present invention, PPP is chilled to approximately about 4⁰C for approximately about 10 minutes. A chemical precipitation agent, e.g.,, ethanoi, is then added to the cooled PPP and the mixture is allowed to incubate, for example, for

25 approximately about 10 minutes. The mixture is then ceiitrifuged for approximately about

5 to 10 minutes at approximately about 4 to 2(FC. The supernatant is then decanted The precipitated and centrifuged pellet of concentrated proteins is resυspended in plasma at a temperature of approximately about 37°C for approximately about I to 10 minutes

30 C. Filtration

An alternative method for concentrating one or more proteins and/or substances from whole blood, blood plasma or a component or fraction thereof such as WI* and/or PRP, involves filtration, e.g.. centrifugal filtration, hollow fiber filtration, membrane 26 filtration and/or gel filtration In membrane filtration, the permeate comprises molecules smaller than the pores of the membrane or filter. Methods to encourage permeation of the small molecules through the membrane include, for example, a vacuum, suction or negative pressure on the permeate side, a positive pressure on the concentrating side, 5 gravity and hydrophilic forces, hi one embodiment of this method, centrifugation may be employed to encourage permeation. Centrifugation filtration devices for protein concentration useful in the practice of this embodiment include, but are not limited to, iCON™ concentrators (Pierce Biotechnology), Macrosep® centrifugal devices (Pal! Corp) and Centricon centrifugal filter units (Millipore). As an alternative, hollow fiber filtration

10 devices can be employed, such as MicroPros® hollow fiber modules (Spectrum Labs) In gel filtration, an absorbing substance, e.g., polyacryjamide beads, concentrates proteins by selectively absorbing or taking up small molecules, e.g, between about 1.8K and 3OK MW, and associated water. Alternate e filtration techniques may include the use of one or more filter devices, which may remove small molecules and water but retain the desired

15 protein(s), e.g. , fibrinogen with a MW of 340 kDa and/or Factor Xl Il with a MW of 320 kDa. Various filter devices that may be used according to one or more embodiments of the present method include hollow fiber filter devices wherein the sample flows through the lumen of a hollow fiber while small molecules from the sample are passed through the liber walls, eg , through pores., thereby concentrating the proteins of interest. Another

20 filtration technique that may be used according to one embodiment of the present method is tangential filtration wherein fluid is forced through a membrane and the small molecules permeate through while large molecules are collected on the membrane surface.

I). Dialysis

25 An alternative method for concentrating one or more proteins and/or substances from whole blood, blood plasma or a component or fraction thereof such as PPP and/or FRP that may be used includes dialysis, e.g., membrane dialysis. Dialysis may be used, for example, to adjust a protein sample from one buffer to another, in adjusting the metal and salt ion concentrations, and in the removal of unwanted small molecules. In one

30 embodiment, dialysis is used to remove a salt, e.g., ammonium sulfate, previously employed to precipitate a protein or substance of interest. A dialysis membrane is generally made of cellulose acetate. In addition, the membrane is semi -permeable, i.e. , molecules below a specified molecular weight can readily pass through the membrane 27 whereas larger molecules cannot Dialysis membranes are commercially available with a wide variety of molecular weight cutoffs. For example, 10,000 and 4O₅OOO da! ton membranes aie typically used for protein dialysis.

5 E. Chromatography

An alternative method for concentrating one or more proteins and/or substances from whole blood, blood plasma or a component or fraction thereof such as PPP and/or PRP is chromatography. Chromatography generally involves a sample, or sample extract. dissolved in a mobile phase, which may be a gas. a liquid or a supercritical fluid, for

10 example The mobile phase is forced through an immobile, immiscible stationary phase.

The phases are chosen such that components of the sample have differing solubilities in each phase. A component that is quite soluble in the stationary phase will take longer to travel through it than a component that is not very soluble in the stationary phase but very soluble in the mobile phase. As a result of these differences in mobilities, sample

15 components will become separated from each other as they travel through the stationary phase. Either the slower mobility or faster mobility components can be chosen for isolation and concentration. One or more forms of chromatography may be used, for example, liquid chromatography, ion exchange chromatography and/or affinity chromatography may be used. Ion exchange chromatography separates charged

20 substances via column materials that carry an opposite charge. ^'The ionic groups of the exchanger coiumnCs) are covaiently bound to a gel matrix, for example, and are compensated by small concentrations of counter ions, which are present in a buffer When a sample is added to the column, an exchange with the weakly bound counter ions takes place. Affinity chromatography separates substances, e.g., biomolecules, via affinity

25 binding. Affinity chromatography can enable purification of a biomoϊectsie, e.g., a protein, with, respect to its function and/or individual chemical structure For example, a substance to be purified or concentrated is specifically and reversibly adsorbed or chemically bound to a ligand or binding substance. The ligand is generally immobilized by a covalent bond to a chromatographic bed material or matrix materia!. Samples are

30 applied under favorable conditions for their specific binding to the ligand. Substances of interest are consequently bound to the ligand while unbound substances are washed away or removed. Recovery of bound substances of interest may then be achieved by changing experimental conditions to favor desorption from the ligand. 28

F, Electrophoresis

As an alternative, electrophoresis may be employed to concentrate one oi more proteins and/or substances from whole blood. Mood plasma or a component or fraction 5 thereof such as PPP and/or PRP. Electrophoresis may be used to separate substances based on size, electric charge and other physical properties, In gel electrophoresis, molecules are forced across a span of gel, motivated by an electrical current In capillary electrophoresis, the application of high voltages across buffer filled capillaries is used to achieve separations. 10

G. Dehydration

An alternative method for concentrating one or more proteins and/or substances from whole blood, blood plasma or a component or fraction thereof such as PPP and/or PRP that may be used is dehydration Dehydration may be used to concentrate plasma

15 proteins by partial or complete removal of water from the blood or plasma. Removing water from blood or plasma increases the concentration of each protein in the blood or plasma Dehydration may be accomplished, for example, by the addition of energy (heat) to drive out water, by the addition of a material, e.g , hydrophiiic polymer materials such as polyacryiamide beads, or by the addition of a dehydration agent, such as an alcohol.

20 which removes and/or absorbs water molecules.

XlIl, Fibrin Compositions of the Present Invention

Hie present invention provides fibrin compositions and methods for making the same In one embodiment, all of the components of the fibrin composition are autologous.

25 i.e., derived from the patient to whom the fibrin composition is to be administered (the recipient of the composition). In addition, methods are provided for the production of autologous thrombin (AT) and AT compositions for use in the preparation of the fibrin compositions of the invention.

For instance, whole blood can be obtained from a patient using known techniques

30 Optionally, the whole blood is processed into platelet poor plasma and/or platelet rich plasma Blood plasma proteins, including thrombin and fibrinogen, are then extracted from the whole blood {and/or components or fractions thereof) and combined to generate an autologous fibrin composition, i.e., a fibrin composition having autologous thrombin and autologous fibrinogen

In addition, provided herein are fibrin compositions having one or more non- autologous components and/or recombinant components, such as thrombin and/or 5 fibrinogen, as described herein

In one embodiment whole blood is collected from the same patient to whom the fibrin composition is to be administered, i.e., the recipient of the composition. Additional sources of whole blood include, for example, single donor human whole blood, pooled human whole blood, human blood products comprising platelets and plasma, e.g , from a 10 blood bank, single donor animal whole blood, pooled animal whole blood and animal blood products comprising platelets and plasma.

In another embodiment, fibrinogen, e.g., autologous fibrinogen, recombinant fibrinogen, is added to a platelet gel composition to accelerate the coagulation of the platelet gel, e.g. , to speed up the clotting (gelling) time. Rapid coagulation time is a 15 desired feature of such a fibrin composition, e.g., during controlled delivery of the composition into tissue, as if reduces leakage or backbleed.

Figures 2-7 are How diagrams of various embodiments of fibrin compositions, which are further detailed below, in accordance with the present invention.

20 A. PPP-Thrombin, PRP, PPP-Protein:

Platelet rich plasma (PRP) and platelet poor plasma (PPP) are formed, for example, by centrifuging a quantity of ami coagulated whole blood, e.g.,, that was previously drawn from the patient. The PPP is then divided into two portions. Thrombin is then derived from the first portion of the PPP One or more proteins, e.g., fibrinogen, is concentrated

25 and removed from the second portion of the PPP. The thrombin, the concentrated protein and the PRP are then mixed together to form a fibrin sealant composition according to one embodiment of the present invention.

Alternatively, PRP and PPP are formed, for example, by centrifuging a quantity of anticoagυlated whole blood, e.g . that was previously drawn from the patient One or

30 more proteins, e.g.. fibrinogen, is concentrated and removed from the PPP Thrombin is then derived from the PPP resulting from the protein concentration process The thrombin, the concentrated protein and the PRP are then mixed together to form a fibrin sealant composition 30

PPP ma j be divided into two portions Thrombin, e.g , autologous thrombin, may then be derived from the first portion of the PPP f^jor example, a compound that reverses the effect of the anticoagulant pjesent in the PPP may be added to the fhst poition of PPP. and a clot or coagulated mass ma> be allowed to form The clot or coagulated mass ma> 5 then be triturated and the resulting serum, containing thrombin, mav be collected One oi rnoie proteins, c jf., fibrinogen, is concentrated, foi example, as described beiein, and remo\ ed from the second portion of the PPP I he thrombin, the concentrated protein and the PfIP are then mixed together to form a fibrin composition If the concentrated protein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet

10 rich fibrin sealant composition

In one embodiment of the piesent i mention, one ot more proteins, e.g., fibrinogen, is concentrated, for example, as described herein, and removed from the PPP Thrombin is then derived from the PPP resulting from the protein concentration process For example, a compound that reverses the effect of the anticoagulant present in the resultant

15 PPP may be added and a clot or coagulated mass may be allowed to form The clot or coagulated mass may then be triturated and the resulting serum, containing thrombin, may be collected The thrombin, the concentrated protein and the PRP are then mixed together to form a fibrin composition according to one embodiment of the present i mention If the concentrated protein comprises fibrinogen, then the fibiin composition may be used, few

20 example, as a platelet rich fibrin sealant composition

B. PRP-Thrombin, FRP, PPP-Protein:

As an alternative, PRP and PPP are formed, for example, by centrifuging a quantit) of anti coagulated whole blood, e.g.. that was pre\iously drawn from the patient

25 Hie PRP is then divided into two portions Thrombin is then derived from the first portion of the PRP One or mote proteins, e.g , fibrinogen, is concentrated and renio\ ed from the PPP J he thiombin, the concentrated piotein and the second portion of the !¹¹RP are then mixed together to form a fibrin sealant composition

In one embodiment of the present i mention, PRP ina> be divided into two

30 portions Thrombin, (.^».#., autologous thrombin, may then be derived from the first portion of the PRP For example, a compound that lev erses the effect of the anticoagulant present in the PPP may be added to the first portion of PPP, and a clot or coagulated mass may be allowed to foim The clot oi coagulated mass may then be triturated and the resulting 3 1 serum, containing thrombin, may be collected One or more proteins, e.g., fibrinogen, is concentrated, for example, as described herein, and removed from the PPP Hie thrombin, the concentrated protein and the second portion of the PRP are then mixed together to form a fibrin composition according to one embodiment of the present invention If the 5 concentrated protein comprises fibrinogen, then the fibrin composition may be, for example, used as a platelet rich fibrin sealant composition,

C. R-Thrombin, PRF, PPP-Protehi:

In another alternative embodiment of the present invention, PRP and PPP are 10 formed, for example, by centrifuging a quantity of anti coagulated whole blood, e,g , that was previously drawn from the patient. One or more proteins, e.g.., fibrinogen, is concentrated, for example, as described herein, and removed from the PPP Recombinant thrombin, the concentrated protein and the PRP are then mixed together to form a fibrin composition according to one embodiment of the present invention. If the concentrated 15 protein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet rich fibrin sealant composition

D. PPP-Thrombin, PRP, PRP-Protein:

In another alternative embodiment of the present invention, PRP and PPP are

20 formed, for example, by centrifuging a quantity of anticoaguiated whole blood, e.g., that was previously drawn from the patient. Thrombin is then derived from the PPP. For example, a compound that reverses the effect of the anticoagulant present in the PPP may be added to the PPP, and a clot or coagulated mass may be allowed to form The clot or coagulated mass may then be triturated and the resulting serum, containing thrombin, may 25 be collected. The PRP is then divided into two portions. One or more proteins, e.g., fibrinogen, is concentrated, for example, as described herein, and removed from the first portion of PRP. The thrombin, the concentrated protein and the second portion of PRP are then mixed together to form a fibrin composition according to one embodiment of the present invention. If the concentrated protein comprises fibrinogen, then the fibrin 30 composition may be used, for example, as a platelet rich fibrin sealant composition 32

E. PRP-Thrombin, PRP, PRP-Protein:

In another alternative embodiment of the present invention, PRP is formed, for example, by centrifughig a quantity of an ti coagulated whole blood, e.g., that was previously drawn from the patient. The PRP is then divided into three portions. ^'Thrombin 5 is then derived from the first portion of the PRP. For example, a compound that reverses the effect of the anticoagulant present in the PRP may be added to the first portion of PRP, and a clot or coagulated mass may be allowed to form. The clot or coagulated mass may then be triturated and the resulting serum, containing thrombin, may be collected One or more proteins, e.g., fibrinogen, is concentrated, for example, as described herein, and

10 removed from the second portion of PRP. The thrombin, the concentrated protein and the third portion of PRP are then mixed together to form a fibrin composition according to one embodiment of the present invention. If the concentrated protein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet rich fibrin sealant composition.

15 In another alternative embodiment of the present invention, PR.P is formed, for example, by centrifuging a quantity of anti coagulated whole blood, e.g., that was previously drawn from the patient. The PRP is then divided into two portions. One or more proteins, e.g , fibrinogen, is concentrated, for example, as described herein, and removed from the first portion of PRP. Thrombin is then derived from the PRP resulting

20 from the protein concentration process. For example, a compound that reverses the effect of the anticoagulant present in the resultant PRP may be added to the PRP, and a clot or coagulated mass may be allowed to form The clot or coagulated mass may then be triturated and the resulting serum, containing thrombin, may be collected. The thrombin, the concentrated protein and the second portion of PRP are then mixed together to form a

25 fibrin composition according to one embodiment of the present invention. If the concentrated protein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet rich fibrin sealant composition.

F. R-Thrombin, PRF, PRP-Prolein:

30 In another alternative embodiment of the present invention. PRP is formed, for example, by centrifuging a quantity of anti coagulated whole blood, e.g., that was previously drawn from the patient The PRP is then divided into two portions. One or more proteins, e.g , fibrinogen, is concentrated, for example, as described herein, and 33 removed from the first portion of PRP. Recombinant thrombin, the concentrated protein and the second portion of PRP are then mixed together to form a fibrin composition according to one embodiment of the present invention. If the concentrated proiein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet 5 rich fibrin sealant composition.

G. PPP- Thrombin, PRP, K-Protein:

In another alternative embodiment of the present invention. PRP and PPP are formed, for example, by centrifuging a quantity of anti coagulated whole blood, e.g., that

10 was previously drawn from the patient. Thrombin is then derived from the PPP. For example, a compound that reverses the effect of the anticoagulant present in the PPP may be added to the PPP, and a clot or coagulated mass may be allowed to form. The clot or coagulated mass may then be triturated and the resulting serum, containing thrombin, may be collected The thrombin, one or more recombinant proteins, e.g., recombinant

15 fibrinogen, and PRP are then mixed together to form a fibrin composition according to one embodiment of the present invention. If the concentrated protein comprises fibrinogen, then the fibrin composition may be used, for example, aa a platelet rich fibrin sealant composition.

20 M. PRP-Thrombin, PRP, R-Protein: hi another alternative embodiment of the present invention, PRP is formed, for example, by centrifuging a quantity of anti coagulated whole blood, e.g.. that was previously drawn from the patient The PRP is then divided into two portions. Thrombin is then derived from the first portion of the PRP For example, a compound that reverses

25 the effect of the anticoagulant present in the PRP may be added to the PRP, and a clot or coagulated mass may be allowed to form. The clot or coagulated mass may then be triturated and the resulting serum, containing thrombin, may be collected. The thrombin, one or more recombinant proteins, e.g., recombinant fibrinogen, and the second portion of the PRP are then mixed together to form a fibrin composition according to one

30 embodiment of the present invention. If the concentrated protein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet rich fibrin sealant composition. 34

I. R-Thrombin, PRP. R-Protein:

In another alternative embodiment of the present invention, PRP is formed, for example, by centrifughig a quantity of an ti coagulated whole blood, e.g., that was previously drawn from the patient. Recombinant thrombin, one or more recombinant 5 proteins, e.g., recombinant fibrinogen, and PRP are mixed together to form a fibrin composition according to one embodiment of the present invention If the concentrated protein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet rich fibrin sealant composition.

10 JL PP P-Thrombin, PPP. PPP- Protein:

In another alternative embodiment of the present invention, PPP is formed, for example, by centrifuging a quantity of anti coagulated whole blood, e.g., that was previously drawn from the patient. The PPP is then divided into three portions Thrombin is then derived from the first portion of the PPP. For example, a compound that reverses

15 the effect of the anticoagulant present in the PPP may be added to the PPP₅ and a clot or coagulated mass may be allowed to form. The clot or coagulated mass may then be triturated and the resulting serum, containing thrombin, may be collected One or more proteins, e.g., fibrinogen, is concentrated, for example, as described herein, and removed from the second portion of the PPP. The thrombin, the concentrated protein and the third

20 portion of PPP are then mixed together to form a fibrin composition according to one embodiment of the present invention. If the concentrated protein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet poor fibrin sealant composition.

In another alternative embodiment of the present invention, PPP is formed, for

25 example, by centrifiiging a quantity of anti coagulated whole blood, e.g., that was previously drawn from the patient. The PPP is then divided into two portions. One or more proteins, e.g , fibrinogen, is concentrated, for example, as described herein, and removed from the first portion of the PPP Thrombin is then derived from the PPP resulting from the protein concentration process. For example, a compound that reverses

30 the effect of the anticoagulant present in the resultant PPP may be added to the PPP, and a clot or coagulated mass may be allowed to form. The clot or coagulated mass may then be triturated and the resulting serum, containing thrombin, may be collected. The thrombin, the concentrated protein and the second portion of PPP are then mixed together to form a 35 fibrin composition according Io one embodiment of the present invention ϊf the concentrated protein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet poor fibrin sealant composition

5 K. PRP-Thrombin, PPP, PPP-Protein:

In another alternative embodiment of the present invention, PRP and PPP are formed, for example, by centrifuging a quantity of anti coagulated whole blood, e.g., that v, as previously drawn from the patient Thrombin is then derived from the PRP, For example, a compound that reverses the effect of the anticoagulant present in the PRP may

10 be added to the PRP, and a clot or coagulated mass may be allowed to form. The clot or coagulated mass may then be triturated and the resulting serum, containing thrombin, may be collected. The PPP is divided into two portions. One or more proteins, e.g., fibrinogen, is concentrated, for example, as described herein, and removed from the first portion of the PPP. The thrombin, the concentrated protein and the second portion of the PPP are then

15 mixed together to form a fibrin composition according to one embodiment of the present invention If the concentrated protein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet poor fibrin sealant composition.

L. ft-Throtnbin, PPP, PPP-Protein:

20 In another alternative embodiment of the present invention, PPP is formed, for example, by centrifuging a quantity of anti coagulated whole blood, e.g., that was previously drawn from the patient. The PPP is then divided into two portions. One or more proteins, e.g , fibrinogen, is concentrated, for example, as described herein, and removed from the first portion of the PPP. Recombinant thrombin, the concentrated

25 protein and the second portion of the PPP are then mixed together to form a fibrin composition according to one embodiment of the present invention If the concentrated protein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet poor fibrin sealant composition.

30 M. PPP-Thrombin, PPP, PRP-Protein:

In another alternative embodiment of the present invention. PRP and PPP are formed, for example, by centrifuging a quantity of anti coagulated whole blood, e.g , that was previously drawn from the patient. The PPP is then divided into two portions. 36

Thrombin ia then derived from the first portion of the PPP. For example, a compound that reverses the effect of the anticoagulant present in the PPP may be added to the PPP₅ and a cloi OT coagulated mass may be allowed to form. The clot or coagulated mass, may then be triturated and the resulting serum, containing thrombin, may be collected. One or more 5 proteins, e.g., fibrinogen, is concentrated, for example, as described herein, and removed from the PRP. The thrombin, the concentrated protein and the second portion of PPP are then mixed together to form a fibrin composition according to one embodiment of the present invention If the concentrated protein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet poor fibrin sealant composition.

10

N. PRP-Thrombin, FPP, PRP-Protein:

In another alternative embodiment of the present invention, PRP and PPP are formed, for example, by centrifugiπg a quantity of anti coagulated whole blood, e.g., that was previously drawn from the patient. The PRP is then divided into two portions

15 Thrombin is then derived from the first portion of the PRP For example, a compound that reverses the effect of the anticoagulant present in the PRP may be added to the PRP, and a clot or coagulated mass may be allowed to form The clot or coagulated mass may then be triturated and the resulting serum, containing thrombin, may be collected. One or more proteins, e.g.. fibrinogen, is concentrated, for example, as described herein, and removed

20 from the second portion of the PRP The thrombin, the concentrated protein and the PPP are then mixed together to form a fibrin composition according to one embodiment of the present invention. If the concentrated protein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet poor fibrin sealant composition In another alternative embodiment of the present invention, PiIP and PPP are

25 formed, for example, by centrifuging a quantity of anti coagulated whole blood, e.g., that was previously drawn from the patient. One or more proteins, e.g., fibrinogen, is concentrated, for example, as described herein, and removed from the PRP. Thrombin is then derived from the PRP resulting from the protein concentration process For example, a compound that reverses the effect of the anticoagulant present in the resultant PRP may

30 be added to the PRP. and a clot or coagulated mass may be allowed to form. The clot or coagulated mass may then be triturated and the resulting serum, containing thrombin, mas- be collected The thrombin, the concentrated protein and the PPP are then mixed together to form a fibrin composition according to one embodiment of the present invention If the 37 con centra ted protein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet poor fibrin sealant composition

O. R-TIi mπi bin, FPP, PRP-Protein:

5 In another alternative embodiment of the present invention, PSlP and PPP are formed, for example, by centrifuging a quantity of antlcoaguiated whole blood, e.g., that was previously drawn from the patient. One or more proteins, e.g , fibrinogen, is concentrated, for example, as described herein, and removed from the PfIP, Recombinant thrombin, the concentrated protein and the PPP are then mixed together to form a fibrin 10 composition according to one embodiment of the present invention. If the concentrated protein comprises fibrinogen, then the fibrin composition may be used, for example, as a platelet poor fibrin sealant composition.

P. PPP-Th rom bin, PPP, R-Protein:

15 In another alternative embodiment of the present invention, PPP is formed, for example, by centrifuging a quantity of anti coagulated whole blood, e.g., that was previously drawn from the patient. The PPP ia then divided into two portions Thrombin is then derived from the first portion of the PPP. For example, a compound that reverses the effect of the anticoagulant present in the PPP may be added to the PPP, and a clot or

20 coagulated mass may be allowed to form. The clot or coagulated mass may then be triturated and the resulting serum, containing thrombin, may be collected The thrombin, one or more recombinant proteins, e.g., recombinant fibrinogen, and the second portion of the PPP are then mixed together to form a fibrin composition according to one embodiment of the present invention. If the concentrated protein comprises fibrinogen,

25 then the fibrin composition may be used, for example, as a platelet poor fibrin sealant composition.

O- PRP-Thrombin, PPP, R-Protein:

In another alternative embodiment of the present invention, PRP and PPP are

30 formed, for example, by centrifuging a quantity of anti coagulated whole blood, e.g., that was previously drawn from the patient. Thrombin is then derived from the PRP. For example, a compound that reverses the effect of the anticoagulant present in the PRP may be added to the PRP, and a clot or coagulated mass may be allowed to form The clot or 38 coagulated mass may then he triturated and the resulting serum, containing thrombin, may be collected The thrombin, one or more recombinant proteins, e.g . recombinant fibrinogen, and PPP aie then mixed togetheϊ to form a fibϊin composition accoiding to one embodiment of the present irn ention If the concentrated protein comprises fibrinogen. 5 then the fibrin composition may be used, foi example, as a platelet poor fibrin sealam composition

R. R-Thromfoin, PPP. R-Protein:

In another alternative embodiment of the present invention, FPP is formed, for 10 example, b> centrifugiπg a quantity of anti coagulated whole blood. e.g , that was pte\ iously dtawn fiorø the patient Recombinant thrombin, one or mote recombinant proteins, e.g , recombinant fibrinogen, and PPP are mixed together to form a fibrin composition according to one embodiment of the present in\ ention If the concentrated protein comprises fibrinogen, then the fibrin composition mav be used, for example, us a 15 platelet poor fibrin sealant composition

XlV. Therapeutic Applications for the Compositions of the Invention

A composition of the present invention ma\ be used as a haemostatic agent, for sealing a "wound such as a smgical "wound OΪ a chionic "wound, e.g , a chionic υlcei, a

20 wound healing agent, e.g.. a cutaneous wound healing agent, andVor agents or \ eliicles for the deiiveiy of one or more ecus, phaimaceutical agents, therapeutic agents, medical agents and/or biological agents For example, a composition of the present invention may be used in plastic surgers or bone repair and or reconstruction In another embodiment, a composition, e.g., a fibrin composition, may be injected into heart tissue, e.g . myocardial

25 tissue The injection of a fibrin composition of the present invention into tissue ma\ provide many features and promoters of healthy healing of injured or diseased tissue A composition of the present invention raa\ piovide many biologicall> acthe agents that can facilitate health) healing of tissue and potentially local regeneration of tissue A number of agents may be found in one embodiment of the present invention.

30 platelet agents such as, foi example, cytokines (including II -l β_ IL-6, TNF-α), chcmokines (including ENA-78 (CXCL.5), IL-8 {CXCL8}, MCP-3 (CCL7), MIP-I α (CCL3), NAP-2 (CXCL7), PF4 (CXCL4), RANTES (CCL5)), inflammatory mediators (including PGE2), matrix metal! opt oteinases, and growth factois (including Angiopoitin- 1 , bFGF, EGF, HGF, IGF-L IGF-IL PDGF AA and BB, TGF-β I . 2, and 3, and VBGF) Multiple agents found in a fibrin com position of the present invention may have an effect in regards to facilitating wound healing. For example, one or more agents found in a fibrin composition of the present invention may play a role in the recruitment of 5 circulating cells to the injured site. One or more agents found in a fibrin composition of the present invention may play a role in the stimulation of local angiogenesis. It is believed that the various agents that may he found in a fibrin composition of the present invention may promote healthy remodeling of injured tissue

In one embodiment of the present invention, a composition of the present invention

10 may be used to improve cell retention and cell surv ival in a cell transplantation technique.

For example, a fibrin composition of the invention may provide a very rich growth medium for the transplanted cells and/or help hold the transplanted cells in place until they have had a chance to integrate into the target tissue. A fibrin composition of the present invention may prevent injected or transplanted celis from being "washed out" soon after

15 injection or delivery

XV. Dosages and Routes of Administration

In certain embodiments, the compositions disclosed herein include pharmaceutical agents, therapeutic agents, medical agents and/or biological agents that may be

20 administered at dosages of at least about 0,01 to about 100 mg/kg, about 0 1 to about 50 rag/kg, or about 0. S to about 30 mg/kg, of body weight, although other dosages may be administered The amount administered may vary depending on various factors including, but not limited to. a particular agent chosen, the disease, and whether prevention or treatment is to be achieved.

25 In certain embodiments, compositions disclosed herein include sense or antisense nucleic acid molecules. Administration of sense or antisense nucleic acid molecules may be accomplished through the administration of the nucleic acid molecule (see, for example, Feigner et «/., U S Pat. No, 5,580,850, Pardoll et uL Immunity, 3' 165 ( 19^QS); Stevenson ci «/., Immunol., Rev , 145: 21 1 (1995); Moiling, MoI Med., 75. 242 (1997);

30 Donnelly etal., Ann. N.Y. Acad. ScL 772: 40 ( 1995); Yang etui., MoI Med Today, £

476 (!996), Abdallah et «/., Biol Cell, 85: 1 (1995); Wolff*'/ «/., Science, 247: 1455 (1990), Tπpathy et uL PNAS, OJ_. 1 1557 (1004), Tripathy et CtL PNAS, 93 10876 (1996); Tπpathy et ui.. Nature Med,, 2, 545 ( 1996); Tsurυmi e/al., Cir., 94: 3281 (1996); 40

Baenigartner c^«://., Circu]aiioii, %: 1 ( 1907); Un cf a/.. Hypertension, 26: 847 ( 1000)) Pharmaceutical formulations, dosages and routes of administration for nucleic acids are generally disclosed, foi example, in Feigncϊ et al., Mψra.

The amount of ceils, pharmaceutical agents, therapeutic agents, medical agents 5 and/or biological agents administered via a composition of the present im entioπ is selected based on the particular indication to be treated. The compositions of the invention may also amenable to chronic use for prophylactic purposes.

A composition of the present invention ma> be injected epicardiaMj . endocardial Iy, transvascularly and/or percutaneous! y. In one embodiment, a physician may perform one

10 or more epi cardial injections of a fibrin composition into tissue {<',£^■, via open chest surgery¹, thoracoscope surgery, or sub-xiphoid access surgery), or a physician may perform one or more endocardial or tran avascular injections of a fibrin composition into tissue {e.g., vta a percutaneous approach) In another embodiment, a physician may perform one or more intramyoeardial injections of a fibrin composition, by epi cardial Iy.

15 endocardialiy, Iransvasculariy (percutaneous) routes. In yet another embodiment, a fibrin composition may be injected or delivered into injured, wounded and/or ischemic tissue, v.g , ischemic cardiac tissue. In another embodiment, a fibrin composition may be injected into aneurysms and/or pseudo aneurysms to relieve pressure and facilitate vessel healing. In addition, a fibrin composition may be injected into an anemysmic sac during

20 stenting {e.g., AAA stenting) to relieve pressure, facilitate healing of a vessel and prevention of leaks. e.g , eiidoleaks

The invention has been described with reference to various embodiments and will be further described by reference to the following detailed examples It is understood, however, that there are many extensions, v ariations, and modifications on the basic theme

25 of the present invention beyond that shown in the examples and detailed description. which are within the spirit and scope of the present invention

EXAMPLES

The present invention will now be described with reference to the fo! low ing 30 specific, non-limiting examples 41

Example 1 Autologous _.Thrombin _.Composition and Method of Preparation

An autologous thϊombin composition ha\ ing an extended table-life is prepated from a single donor's whole blood, blood components, or a combination thereof Non- 5 anticoagulatcd whole blood, ami coagulated whole blood, or components thereof such as platelet-rich plasma, platelet-poor plasma, and or plateiet-fiee plasma obtained tiom the donor is aspirated into a chamber or vessel If anti coagulated \\ hole blood or a component thereof is used, it is contacted with an effective amount of a compound or material that re\ erses the anticoagulant Clotting is initiated and/or accelerated by the use of a contact

10 activation agent, e.g., an agent that initiates clotting via the intrinsic clotting cascade or pathway, such as glass, diatomaceous earth, ceiaroic. kaolin, and the like Complete clotting is achieved within twenty minutes at room temperature, which time may be accelerated by increasing the temperature, for example, to physiological temperature levels, e g , 37°C As an alternative or in addition thereto, one or more extrinsic

15 coagulation pathway initiation agents, i.e., an agent that initiates clotting via the extrinsic clotting cascade or pathway, such as thromboplastin, a phospholipid, a derivative thereof, or a combination thereof, is used to initiate and/or accelerate clotting

For example, whole blood from a single donor is contacted with thromboplastin, glass and calcium chloride A clot is generated within about 5 minutes cw less, e.g., within

20 about 2 to about 4 minutes, at room temperature Thrombin is then harvested from the clot by squeezing the clot filtering the throinbin-rich seium, and contacting the thrombin with a stabilization agent, e g , an alcohol such as ethanol, to preserve its biological activity, thus providing an autologous thrombin composition having an extended table-life Contacting thrombin with ethanol, eg , 15% to 25% \/v ethanol, has been shown by the

25 inventors to preserve the biological activity of the thrombin by at least 3 hours Biological activity of the thrombin may be presett ed further, for more than three houis, by refrigesating the thrombi n-ethanol røixtute for example, storing the mixture at 4"T.

Contacting the autologous thrombin composition with platelet rich plasma, platelet poor plasma, and 'or whole blood dilutes the concentration of ethanol present in the

30 composition to a lev el that docs not inhibit the formation of a gel, and an autologous platelet gel is provided

In experiments using the autologous thrombin composition prepared by method, an autologous platelet gel was formed in less than 20 seconds, even using an autologous 42

thrombin composition that had been stored for three hours. In addition, after six hours of refrigeration, the autologous thrombin composition triggered autologous platelet gel formation after contact with each of PRP and PPP ThiombJn-rich serum, after storage at room temperature, may trigger ge! formation with PiIP and/or PPF after 24 hours, 5 Thrombi n-rieh serum may be used to form a gel with whole blood, PRP, PPP, pooled plasma, fresh frozen plasma, and/or cryo precipitate. In addition, thrombin -rich seairø may be combined with other activators, or scaffolding substances like collagen and delivered as a hemostatic agent and/or as a wound healing agent, for example. The thrombi n-rich serum may be used to treat aneurysms, or pseudo-aneurysms, or as an 10 adjunct to stent grafting by clotting off the aneυrismal sac thereby preventing the occurrence of endoleaks or sac ruptures In addition, the thrombi n-rich serum may be used as a topical hemostat to prevent oozing from organs

Example 2

PRP and PPP, e.g., autologous PRP and PPP, are prepared from anti coagulated whole blood, for example, as described herein A concentrated plasma (plasma concentrate) rich in clotting proteins, such as, but not limited to, fibrinogen, Factor XIII, Factor VfTl. and vWF, is prepared from the PPP fraction

20 In one embodiment of the present invention, an organic reagent, such as ethanol, isopropanol or PEG, may be used to precipitate one or more substances, e.g., clotting proteins, followed by centrifugation and/or filtration. One or more substance, e.g , clotting proteins, may also be concentrated by precipitation using an inorganic, salt(s) or a salt solutions), such as ammonium sulfate. In one embodiment of the present invention, a

25 filter device may be employed to remove water and small molecules from the plasma upon application of a pressure differential The plasma concentrate, PRP and thrombin may then be combined in various ratios to prepare customizable fibrin compositions that may be useful for promoting wound healing, hemostasis and sealing The plasma concentrate is combined with thrombin to prepare a fibrin composition. PRP is combined with

30 thrombin to prepare an autologous platelet gel (APG)

In one embodiment of the present invention, the plasma concentrate may be subjected to one or more additional steps (pre and/or post treatment steps) to further concentrate one or more substance, e.g , clotting proteins. In one embodiment of the 43 present invention, the PRP fraction may be subjected Io additional one or more additional steps (pre-treattnent steps), prior to contacting PRP with the plasma concentrate, to release growth factors into the plasma concentrate matrix.

5 AU publications, patents and patent applications are incorporated herein by reference. While in the foregoing specification this invention has been described in relation to certain embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied 10 considerably without departing from the basic principles of the invention.

Claims

44

WHAT IS CLAIMED IS:

1. A method for preparing a thrombin composition, the method comprising, contacting whole blood, a component thereof or a fraction thereof, with a contact

5 activation agent, an extrinsic coagulation pathway initiation agent, or combination thereof, to generate a coagulated mass in less than about thirty minutes; obtaining thrombin from the mass; and contacting the thrombin with a stabilizing agent to provide a thrombin composition comprising thrombin having a table-life of more than about six hours. 10

2. The method of claim 1, wherein the thrombin is obtained from whole blood, a component thereof or a fraction thereof that has been collected from composition's recipient.

15 3 The method of claim 1 , further comprising contacting the whole blood, component thereof or fraction thereof, with a source of calcium ions.

4. The method of claim 3, wherein the source of calcium ions comprises CaCl; or a salt thereof.

20

5. The method of claim 1, wherein the stabilizing agent comprises a polyol, PEG, ammonium sulfate, a non-polar solvent a polar solvent, a methyl isobutyl ketone alcohol, glycol, tricloroacetic acid, acetate salt, and any combination thereof.

25 6. The method of claim 5, wherein the stabilizing agent comprises ethanol,

7. The method of claim 6, wherein the ethanol is in the range of about 8 % to about 25 % volume/volume.

30 8. The method of claim 6, with the proviso that the whole blood, component thereof or fraction thereof, is not contacted with the ethanol prior to generation of the mass. 45

9 The method of claim 1 , wherein the mass is generated in less than about IO minutes

10 The method of claim 9, wherein the mass is generated in less than about 5 minutes

11 The method of claim 1O₅ v\ herein the mass is generated in less, than about 3 minutes

S 2 The method of claim 1 L wherein the mass is generated in about 1 minute to about 10 3 minutes

13 The method of claim I, wherein the table-life is more than 12 hours

14 The method of claim 13, wherein table-life is up to 24 hours 15

15 The method of claim I, wherein the thrombin composition composes thrombin having biological activity for more than six hours

So The method of claim ! 5, whcϊein the biological activity comprises en/y malic 20 acth ity

17 The method of claim 1, wherein the thrombin composition, when contacted with fibrinogen, is capable of forming a fibrin sealant composition in about 10 seconds or less

25 18 The method of claim S , wherein the fraction of whole blood comprises platelet rich plasma (PRP), platelet poor plasma (PPP), or a combination thereof

1 ^c> The method of claim 1 , wherein the contact activation agent comprises glass wool

30 20 The method of claim 1, wherein, the extrinsic coagulation pathway initiation agent compri ses thromboplastin

21 The thrombin composition prepared by the method of claim 1 46

22. A method of preparing a fibrin composition, the method comprising: fractionating auti coagulated whole blood, a fraction thereof or a component thereof to obtain a composition comprising fibrinogen, and

5 contacting the fibrinogen composition and a thrombin composition to provide a fibrin composition.

23 The method of claim 22. wherein antieoagulated whole blood, a fraction thereof or a component thereof is obtained from the fibrin composition's recipient. 10

24. The method of claim 22, further comprising obtaining a platelet composition comprising platelet rich plasma, platelet poor plasma, or a combination thereof.

25. The method of claim 24, further comprising concentrating plasma proteins present 15 in the platelet composition to provide a plasma protein concentrate, and contacting the concentrate with the fibrinogen composition and the thrombin composition

26. The method of claim 25, wherein the plasma proteins are concentrated by cryoprecipitation, chemical precipitation, filtration, dialysis, chromatography,

20 electrophoresis, dehydration, or a combination thereof

27. The method of claim 26, wherein the plasma proteins are concentrated using ethanol

25 28. The method of claim 22, wherein the thrombin composition comprises autologous thrombin, recombinant thrombin, bovine thrombin, or a combination thereof.

29. The method of claim 28, wherein the thrombin composition comprises autologous thrombin.

30

30. The method of claim 28, wherein the thrombin composition comprises recombinant thrombin. 47

31, The method of claim 22, further comprising contacting the composition with a recombinants produced protein.

32 The fibrin composition prepared by the method of claim 22 5

33. A method of preparing a platelet rich fibrin sealant composition, the method comprising: fractionating ami coagulated whole blood, a fraction thereof or a component thereof to obtain a composition comprising platelets, and

10 contacting the platelet composition with a fibrinogen composition and a thrombin composition to provide a platelet rich fibrin sealant composition.

34 Hie method of claim 33, further comprising concentrating plasma proteins present in the whole blood to provide a protein concentrate; and contacting the platelet 15 composition, the fibrinogen composition and the thrombin composition with the protein concentrate.

35. The method of claim 33, wherein the protein concentrate comprises fibrinogen. Factor XHL Factor YlH₅ von WUlebrancl factor (v\VF). or a combination thereof

20

36. The method of claim 34, wherein the concentrating comprises filtration.

37. The method of claim 53, wherein the thrombin composition comprises recombinant thrombin, autologous thrombin, bovine thrombin, or a combination thereof

25

38. The method of claim 33, wherein the fibrinogen composition comprises autologous fibrinogen, recombinant fibrinogen, or a combination thereof.

39. The platelet rich fibrin sealant composition prepared by the method of claim i^. 30

40. A method of preparing a fibrin composition, the method comprising. 48 contacting a first portion of aπticoagulated whole biood, a fraction thereof or a component thereof w ith a contact activ ation agent and an extrinsic coagulation ρath\sa> initiation agent to pϊovide a coagulated nias^ in Ie^s than about 3ϋ minutes, extracting thrombin from the coagulated mass to provide a thrombin composition, 5 fractionating a second portion of the anti coagulated whole blood, a fraction thereof or a component theieof to obtain a fibrinogen composition and a platelet plasma composition, and contacting the thrombin composition, the fibrinogen composition and the platelet composition to generate a fibrin composition 10

41 The method of claim 40. further comprising contacting the fibrinogen composition, platelet composition, or a combination thereof with a recombinant protein composition

42 The method of claim 40, further comprising contacting the thrombin composition a 15 stabilizing agent to provide a iluombin composition having a tabie-life of more than about

6 hours

43 The method of claim 42, wherein the stabilizing agent comprises a polyol, PEG, ammonium sulfate, a non-polar solx ent, a polai soh ent, a methyl isobutyl ketone alcohol,

20 glycol, tricloroacetic acid, acetate salt, or any combination thereof,

44 rhe method of claim 43, wherein the stabilizing agent comprises ethanol

45 I he method of claim 44, w herein about 8 % to about 25 % \ olumeλ olume ethanol 25 is added to the thrombin composition

46 The method of claim 45, wherein about 10 % volume/volume ethanol is added to the thrombin composition

30 47 The method of claim 42. wherein the thrombin composition has a tabie-life of more than 12 hours 40

48, The method of claim 47, wherein the thrombin composition has a tabie-lϊfe of up to 24 hours

40 The method of claim 40. with the proviso that the ami coagulated whole blood, a 5 fraction thereof or a component thereof is not contacted with ethanol during the generation of the coagulated mass

50 The method of claim 40. wherein the coagulated mass is generated in less than about 10 minutes. 10

51. The method of claim 50, wherein the coagulated mass is generated in less than about 5 minutes.

52, The method of claim 51, wherein the coagulated mass is generated in less than 15 about 3 minutes.

53 The method of claim 52, wherein the coagulated mass is generated in about 1 minute to about 3 minutes.

20 54. The method of claim 40, wherein the first portion comprises platelet rich plasma

(PRP), platelet poor plasma (PPP), or a combination thereof.

55. The method of claim 54, wherein the first portion comprises platelet rich plasma (PRPK

25

56. The method of claim 54. wherein the first portion comprises platelet poor plasma (PFP)

57. The method of claim 40, wherein the second portion comprises platelet rich plasma 30 (PRP), platelet poor plasma (PPP), or a combination thereof.

58. The method of claim 57, wherein the second portion comprises platelet rich plasma (PRP) 50

59. The method of claim 58, wherein the second portion comprises platelet poor plasma (PPP).

5 60, The method of claim 40, further comprising contacting the anti coagulated whole blood, a fraction thereof or a component thereof with a source of calcium ions

61 The method of claim 60. wherein the source of calcium ions comprises CaCb or a salt thereof. 10

62. The method of claim 40, wherein the contact activation agent comprises glass wool

63, The method of claim 40, wherein the extrinsic coagulation pathway initiation agent 15 compri ses thromboplasli n .

64 The method of claim 40, wherein the anticoagulated whole blood, a fraction thereof or a component is obtained from the fibrin composition^'s intended recipient.

20 65. The method of claim 40, wherein the coagulated mass comprises a fibrin clot.

66. The method of claim 40, further comprising contacting the thrombin composition, the fibrinogen composition and the platelet composition with a pharmaceutical agent, therapeutic agent, medical agent, biological agent, or any combination thereof to provide a

25 fibrin composition.

67. The fibrin composition prepared by the method of claim 40